FDA Approves Elotuzumab for Multiple Myeloma Combination Therapy

Share this content:
FDA Approves Elotuzumab for Multiple Myeloma Combination Therapy
FDA Approves Elotuzumab for Multiple Myeloma Combination Therapy

(HealthDay News) -- Empliciti (elotuzumab), in combination with two other drugs, has been approved by the U.S. Food and Drug Administration to treat multiple myeloma. The drug is only approved for patients who have already been given one to three prior therapies for the disease.

Empliciti, a monoclonal antibody, activates the body's immune system to attack and kill multiple myeloma cells, the FDA explained Monday in a news release. It is approved in combination with another FDA-approved treatment for multiple myeloma, Revlimid (lenalidomide), and the corticosteroid dexamethasone.

Empliciti was evaluated in clinical studies involving 646 people whose multiple myeloma returned or didn't respond to prior treatment. Patients who took the three-drug combination including Empliciti had an average disease-progression delay of 19.4 months, compared to 14.9 months among those who took the other two drugs without Empliciti.

Empliciti's most common side effects included fatigue, diarrhea, fever, constipation, cough, peripheral neuropathy, nasal infection, respiratory infection, loss of appetite, and pneumonia.

The drug is marketed by New York City-based Bristol-Myers Squibb.

More Information

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs